drugset / Trial / NCT07234890
Study to Evaluate the Effects of AV-001 on HD-induced Brain Injury.
Phase 2
Recruiting
60 enrolled
London Health Sciences Centre Research Institute
Vasomune Therapeutics, Inc. · collab
RandomizedParallel-groupQuadruple-blindHealth-services research
Summary
Cognitive decline is increasingly recognized among patients receiving maintenance hemodialysis (HD). This can include trouble remembering, slower thinking or mentally feeling foggy. This research is being done to determine if a new medication (AV-001) can protect the brain from injury caused by hemodialysis by strengthening blood vessels in the brain and reducing inflammation. If successful, this research could lead to better protection for the brains of people undergoing regular dialysis, potentially reducing the risk of cognitive decline and stroke.
Timeline
- Start
- 2025-12-16
- Primary completion
- 2027-12-31
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AV-001 | Unknown | 12.5 ug/kg | Intravenous |
| Subject | AV-001 | Unknown | 25 ug/kg | Intravenous |
Indications
No indication recorded.